New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:13 EDTMGNXMacroGenics price target raised to $51 from $35 at Stifel
Stifel increased its price target on MacroGenics as the firm thinks the company is uniquely positioned to benefit from investor enthusiasm for targeted combination therapy in the immuno-oncology space. The firm believes the company has best-in-class technology, while recent data has increased Stifel's confidence in the company's approach. It keeps a Buy rating on the shares.
News For MGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
17:26 EDTMGNXMacroGenics to present Phase 1 margetuximab study data at ASCO
MacroGenics, a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced that clinical data from its Phase 1 study of margetuximab will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology, ASCO, which is being held from May 29 to June 2 in Chicago, Illinois.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use